TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38480632

Group type: EXPERIMENTAL
Intervention: Preoperative 500 mL fluid bolus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 40
Study: 38480922

Group type: EXPERIMENTAL
Intervention: Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2
Number of subjects: 6
Study: 38481024

Group type: EXPERIMENTAL
Intervention: Smoking prevention intervention in SR-settings
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 24
Study: 38481111

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active Surveillance
Number of subjects: 0
Study: 38481147

Group type: EXPERIMENTAL
Intervention: Web-based surveillance and respiratory specimen collection kits; participants monitored weekly for respiratory illness symptoms and collected specimens at symptom onset.
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Web-based surveillance and remote contact tracing; longitudinal specimen collection every 2 days for 14 days.
Number of subjects: 1371
Study: 38481166

Group type: EXPERIMENTAL
Intervention: National Basic Public Health Service Program (NBPHSP) policy
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: PHC providers' capacity and income level
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Patients' engagement in care
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Digital health approaches
Number of subjects: 197
Study: 38481195

Group type: EXPERIMENTAL
Intervention: Peer navigation intervention
Number of subjects: 113

Group type: COMPARATOR
Intervention: Lifetime physical violence
Number of subjects: 113

Group type: COMPARATOR
Intervention: Lifetime sexual violence
Number of subjects: 113
Study: 38481208

Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on glucagon secretion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on GLP-1 secretion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on GIP secretion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on C-peptide secretion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on glucose levels
Number of subjects: 24
Study: 38481209

Group type: EXPERIMENTAL
Intervention: sirolimus 2 mg once a day for a maximum of 60 months
Number of subjects: 15
Study: 38481211

Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedures via blood clot
Number of subjects: 18
Study: 38481293

Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive interactive training program (VICT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparable VR game without executive function training
Number of subjects: 32
Study: 38481318

Group type: EXPERIMENTAL
Intervention: Manual therapies (specific type not detailed)
Number of subjects: 73
Study: 38481504

Group type: EXPERIMENTAL
Intervention: Plasma oxalate (POx) levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Urinary oxalate (UOx) levels
Number of subjects: 45

Group type: COMPARATOR
Intervention: High POx levels (HPO) vs Normal POx levels (NPO)
Number of subjects: 45
Study: 38481666

Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate (LHRH agonist)
Number of subjects: 592
Study: 38481947

Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with ruxolitinib
Number of subjects: 0
Study: 38482290

Group type: EXPERIMENTAL
Intervention: Nudge strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no nudge strategy)
Number of subjects: 0
Study: 38482462

Group type: EXPERIMENTAL
Intervention: CM326 55 mg every two weeks (Q2W)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CM326 110 mg every two weeks (Q2W)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CM326 220 mg every two weeks (Q2W)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CM326 220 mg every four weeks (Q4W)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 38482528

Group type: EXPERIMENTAL
Intervention: 12-week intervention based on pain neuroscience education and therapeutic yoga as a graded exposure to movement exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual cancer-related symptoms care (Control)
Number of subjects: 40
Study: 38482816

Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Primary Arthrodesis (PA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both ORIF and PA
Number of subjects: 43
Study: 38482823

Group type: EXPERIMENTAL
Intervention: Accelerated rTMS (intermittent theta-burst stimulation to the left dorsolateral prefrontal cortex, 600 pulses/session, 8 sessions/day for 5 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Accelerated rTMS
Number of subjects: 9
Study: 38483145

Group type: EXPERIMENTAL
Intervention: 36-week steroid stepwise reduction (SSR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 48-week steroid stepwise reduction (SSR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 36-week SSR
Number of subjects: 90

Group type: COMPARATOR
Intervention: 48-week SSR
Number of subjects: 90
Study: 38483248

Group type: EXPERIMENTAL
Intervention: Weekly oral vitamin D3 (VD3) for 6 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 101
Study: 38483309

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg orally once daily from days 1 to 14 every 3 weeks)
Number of subjects: 40
Study: 38483366

Group type: EXPERIMENTAL
Intervention: Restorative neurostimulation
Number of subjects: 204
Study: 38483402

Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS)
Number of subjects: 1009
Study: 38483412

Group type: EXPERIMENTAL
Intervention: HYPORT (62.5 Gy in 25 fractions)
Number of subjects: 296

Group type: COMPARATOR
Intervention: COPORT (66.6 Gy in 37 fractions)
Number of subjects: 296
Study: 38483418

Group type: EXPERIMENTAL
Intervention: Early-POAF within the first 90 postoperative days
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Late-POAF after the first 90 postoperative days
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Preoperative variables for predicting late-POAF
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Signs of advanced AF substrate (increased right atrial volumes)
Number of subjects: 133
Study: 38483458

Group type: EXPERIMENTAL
Intervention: Patients who reported having a clear plan, agreed with the plan, and intended to follow the plan.
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Patients who reported plans related to follow-up with the primary care provider.
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Patients who reported plans to initiate or adjust medications.
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Patients who reported plans for a specialist visit.
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Patients indicating intent to follow their plan.
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Patients who assessed their plan as clear, agreed with it, and were willing to follow it.
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Patients whose plans involved lifestyle changes.
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Reasons for completely following the plan.
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Reasons for not following the plan.
Number of subjects: 2555
Study: 38483463

Group type: EXPERIMENTAL
Intervention: e-SBI (Electronic Screening and Brief Intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Screening only
Number of subjects: 200
Study: 38483469

Group type: EXPERIMENTAL
Intervention: Yoga intervention (n=102)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control stretching and strengthening intervention (n=102)
Number of subjects: 204
Study: 38483522

Group type: EXPERIMENTAL
Intervention: Narrator disclosure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (BMI) techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High empathy condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither narrator disclosure nor BMI techniques
Number of subjects: 0
Study: 38483534

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) transfusion with high antibody levels (upper 30% of study donors' antibody levels)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 17
Study: 38483543

Group type: EXPERIMENTAL
Intervention: Ketone monoester (KME) ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 38483611

Group type: EXPERIMENTAL
Intervention: Faricimab (6.0 mg up to every 16 weeks after 4 initial Q4W doses)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Aflibercept (2.0 mg Q8W after 3 initial Q4W doses)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Faricimab
Number of subjects: 133

Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 133
Study: 38483633

Group type: COMPARATOR
Intervention: Modified Balloons (MB)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA)
Number of subjects: 200
Study: 38483732

Group type: EXPERIMENTAL
Intervention: Postoperative IL8 levels
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Postoperative IL18 levels
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Preoperative IL concentrations
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: NBM volume
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: NBM atrophy
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Prognostic value of preoperative IL concentrations
Number of subjects: 240
Study: 38483776

Group type: EXPERIMENTAL
Intervention: 24-h replacement interval
Number of subjects: 1240

Group type: COMPARATOR
Intervention: 96-h replacement interval
Number of subjects: 1240
Study: 38483782

Group type: EXPERIMENTAL
Intervention: Selumetinib 100 mg plus Pembrolizumab 200 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Selumetinib 125 mg plus Pembrolizumab 200 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Selumetinib (various doses) plus Pembrolizumab
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Selumetinib plus Pembrolizumab
Number of subjects: 32
Study: 38483869

Group type: EXPERIMENTAL
Intervention: Person-centred multicomponent care transition support
Number of subjects: 0
Study: 38483940

Group type: EXPERIMENTAL
Intervention: Psilocybin (20mg/70kg and 30mg/70kg)
Number of subjects: 24
Study: 38484130

Group type: EXPERIMENTAL
Intervention: c-Jun N-Terminal Kinase Inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38484209

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NAT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Targeted agents
Number of subjects: 177
Study: 38484239

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol preoperatively for 7 days
Number of subjects: 0
Study: 38484251

Group type: EXPERIMENTAL
Intervention: 5 mL/5 injection
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 10 mL/10 injection
Number of subjects: 108
Study: 38484432

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg once daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Prior imatinib
Number of subjects: 156

Group type: COMPARATOR
Intervention: Prior dasatinib
Number of subjects: 156

Group type: COMPARATOR
Intervention: Prior nilotinib
Number of subjects: 156
Study: 38484756

Group type: EXPERIMENTAL
Intervention: Extended postnatal prophylaxis with lamivudine syrup twice per day for 12 months or 1 month after breastfeeding discontinuation, initiated based on maternal viral load measured using Xpert HIV viral load assay.
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Control group following national guidelines for prevention of postnatal transmission of HIV.
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Both groups (intervention and control) regarding HIV-free survival and serious adverse events.
Number of subjects: 1506
Study: 38484795

Group type: EXPERIMENTAL
Intervention: Adolescents with ADHD
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-psychiatric controls
Number of subjects: 62
Study: 38484853

Group type: EXPERIMENTAL
Intervention: Combination of dry needling (DN) and spinal manipulative therapy (SMT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dry needling (DN) only
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) only
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study: 38484976

Group type: EXPERIMENTAL
Intervention: Fish oil (1.9 g/d n-3 PUFAs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control oil (high-oleic safflower oil)
Number of subjects: 40
Study: 38485054

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (40 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 38485184

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered every 2 weeks until disease progression, unacceptable toxicity, or for 24 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 48
Study: 38485188

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 41
Study: 38485189

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (2 mg/kg up to 200 mg for pediatric patients)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 976

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 976
Study: 38485190

Group type: EXPERIMENTAL
Intervention: Nivolumab plus SOC (5-fluorouracil/leucovorin/oxaliplatin/bevacizumab)
Number of subjects: 310

Group type: COMPARATOR
Intervention: SOC (5-fluorouracil/leucovorin/oxaliplatin/bevacizumab)
Number of subjects: 310
Study: 38485210

Group type: EXPERIMENTAL
Intervention: Polypill (fixed-dose combination therapy including two antihypertensive agents, a statin, and aspirin)
Number of subjects: 4415

Group type: COMPARATOR
Intervention: Non-pharmacological intervention (educational training on healthy lifestyle)
Number of subjects: 4415
Study: 38485313

Group type: EXPERIMENTAL
Intervention: 10 mL 0.5% bupivacaine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 152
Study: 38485472

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) during DLT intubation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Traditional mask transnasal oxygen
Number of subjects: 112
Study: 38485473

Group type: EXPERIMENTAL
Intervention: 3 or more periods of at least 7 days' smoking abstinence during pregnancy
Number of subjects: 407

Group type: COMPARATOR
Intervention: No abstinence periods
Number of subjects: 407

Group type: COMPARATOR
Intervention: Reduction of smoking intensity by at least 50%
Number of subjects: 407

Group type: COMPARATOR
Intervention: Reduction of cigarette consumption
Number of subjects: 407
Study: 38485475

Group type: EXPERIMENTAL
Intervention: Community-based multicomponent lifestyle intervention (the ADA programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38485487

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (NO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no inhaled NO)
Number of subjects: 0
Study: 38485490

Group type: EXPERIMENTAL
Intervention: Opioid replacement therapy (ORT) with benzodiazepine (BZD) coprescription
Number of subjects: 46899

Group type: COMPARATOR
Intervention: Opioid replacement therapy (ORT) alone
Number of subjects: 46899
Study: 38485651

Group type: COMPARATOR
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Collagen Matrix (CMX)
Number of subjects: 60
Study: 38485862

Group type: EXPERIMENTAL
Intervention: Hand Eczema Symptom Diary (HESD)
Number of subjects: 280
Study: 38485863

Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 1979

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 1979
Study: 38486069

Group type: EXPERIMENTAL
Intervention: Text-based interventions that increased vaccinations in prior field work (RCT1, NCT05586204)
Number of subjects: 314824

Group type: EXPERIMENTAL
Intervention: Text-based interventions that elevated vaccination intentions in an online study (RCT2, NCT05586178)
Number of subjects: 314824

Group type: EXPERIMENTAL
Intervention: Text-based interventions favoured by scientists and non-experts (RCT3, NCT05586165)
Number of subjects: 314824

Group type: COMPARATOR
Intervention: Encouraging the bundling of COVID-19 boosters and flu shots
Number of subjects: 314824

Group type: COMPARATOR
Intervention: Addressing misconceptions about COVID-19 boosters
Number of subjects: 314824
Study: 38486179

Group type: EXPERIMENTAL
Intervention: Telemedicine-based follow-up with individual treatment plan, computer tablets, and home telemonitoring devices.
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Telemedicine-based follow-up
Number of subjects: 126
Study: 38486192

Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT)
Number of subjects: 68
Study: 38486278

Group type: EXPERIMENTAL
Intervention: Nutrition program delivered to mothers' groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bundled nutrition and parenting program delivered to mothers' groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrition program delivered to mothers' and fathers' groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bundled nutrition and parenting program delivered to mothers' and fathers' groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care health services (control)
Number of subjects: 0
Study: 38486304

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort
Number of subjects: 778

Group type: COMPARATOR
Intervention: Non-COVID-19 cohort
Number of subjects: 778
Study: 38486359

Group type: EXPERIMENTAL
Intervention: Dual-task exergaming telerehabilitation (n=20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Aerobic exercise (AEx) only (n=11)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Attention control (stretching) (n=8)
Number of subjects: 39
Study: 38486776

Group type: EXPERIMENTAL
Intervention: Two-dose primary series of ancestral strain vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monovalent Beta variant booster vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ancestral or variant strain booster vaccine
Number of subjects: 0
Study: 38486810

Group type: EXPERIMENTAL
Intervention: Genetic testing with result disclosure and genetic counseling
Number of subjects: 14
Study: 38487037

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 38487528

Group type: EXPERIMENTAL
Intervention: SON-1010 at 100 ng/kg or higher
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SON-1010 at 50-300 ng/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SON-1010
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 38487573

Group type: EXPERIMENTAL
Intervention: D-HOMES intervention (one-on-one, 3 month coaching intervention)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: D-HOMES intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC; brief diabetes education session and routine care)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 36
Study: 38487818

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration (mean 11 months, IQR 7-14 months)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration in women with GDM history
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration
Number of subjects: 76
Study: 38488039

Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 0
Study: 38488139

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 0
Study: 38488388

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to second-generation antipsychotics
Number of subjects: 0
Study: 38488429

Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 38488572

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38488780

Group type: EXPERIMENTAL
Intervention: Peer comparison intervention
Number of subjects: 38235

Group type: EXPERIMENTAL
Intervention: Guidelines intervention
Number of subjects: 38235

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38235
Study: 38488827

Group type: EXPERIMENTAL
Intervention: MS CATCH (intervention used during clinician visits)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No MS CATCH (control group)
Number of subjects: 50
Study: 38488975

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks (Q4W)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Guselkumab 100 mg every 8 weeks (Q8W)
Number of subjects: 698
Study: 38488976

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO) or sulfasalazine
Number of subjects: 0
Study: 38489057

Group type: EXPERIMENTAL
Intervention: Chloroprocaine 3% Gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38489060

Group type: EXPERIMENTAL
Intervention: Aflibercept treatment
Number of subjects: 0
Study: 38489063

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap + xenogeneic collagen matrix (test group)
Number of subjects: 20
Study: 38489117

Group type: EXPERIMENTAL
Intervention: BNT162b2 30 μg
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: BNT162b2 10 μg (5- to 11-year-olds)
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: BNT162b2 30 μg (12- to 15-year-olds)
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Placebo (5- to 11-year-olds)
Number of subjects: 1485
Study: 38489119

Group type: EXPERIMENTAL
Intervention: B/F/TAF
Number of subjects: 0

Group type: COMPARATOR
Intervention: E/C/F/TAF
Number of subjects: 0